Abstract
Introduction:
Recently CDK4/6 inhibitors have been introduced for the treatment of hormone positive breast cancer resistant to endocrine therapy. Among their side effects, alopecia is often reported being associated to patients' distress and depressive symptoms.
Case report:
We report the case of a 70-year-old woman affected by breast cancer in treatment with Palbociclib, who developed alopecia.Management and Outcome: We prescribed a topical solution with cetirizine. Global photography, trichoscopy and trichogram were assessed. All evaluations demonstrated alopecia improvement.
Discussion:
Currently, no treatment options for CDK 4/6 inhibitors induced alopecia have been proposed. Herein, we report the use of topical cetirizine.
Keywords:
CDK4/6 inhibitors; Topical cetirizine; alopecia; hair loss; palbociblib.
MeSH terms
-
Administration, Topical
-
Aged
-
Alopecia / chemically induced*
-
Alopecia / drug therapy*
-
Antineoplastic Agents / adverse effects*
-
Breast Neoplasms / complications
-
Breast Neoplasms / drug therapy
-
Cetirizine / administration & dosage
-
Cetirizine / therapeutic use*
-
Cyclin-Dependent Kinases / antagonists & inhibitors
-
Female
-
Histamine H1 Antagonists / administration & dosage
-
Histamine H1 Antagonists / therapeutic use*
-
Humans
-
Neoplasm Metastasis / drug therapy
-
Piperazines / adverse effects*
-
Piperazines / therapeutic use
-
Protein Kinase Inhibitors / adverse effects*
-
Protein Kinase Inhibitors / therapeutic use
-
Pyridines / adverse effects*
-
Pyridines / therapeutic use
-
Scalp / pathology
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Histamine H1 Antagonists
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyridines
-
Cyclin-Dependent Kinases
-
palbociclib
-
Cetirizine